Double-blind donepezil-placebo crossover augmentation study of atypical antipsychotics in chronic, stable schizophrenia: A pilot study

S. Craig Risch, Michael D. Horner, Susan R. McGurk, Simmy Palecko, John S. Markowitz, Ziad Nahas, C. Lindsay DeVane

Research output: Contribution to journalArticlepeer-review

21 Scopus citations

Abstract

Thirteen outpatients with chronic but stable schizophrenia received donepezil and placebo augmentation of their maintenance antipsychotic medication regimen. Each subject received in a randomized, counterbalanced order 1) donepezil 5 mg for 6 weeks then donepezil 10 mg for six weeks and 2) placebo donepezil for 12 weeks. Serial ratings of the Positive and Negative Symptom Scale (PANSS) [Kay, S.R., Fiszbein, A., Opler, L.A., 1987. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13(2): 261-276] were performed by a trained rater blind to the donepezil order and condition: at baseline, 12 weeks and 24 weeks. On donepezil as compared to baseline or placebo, there was a significant improvement in PANSS negative scores (p = .018, n = 13). These results are discussed with respect to other studies using cholinesterase inhibitors as an augmentation strategy in schizophrenia.

Original languageEnglish (US)
Pages (from-to)131-135
Number of pages5
JournalSchizophrenia Research
Volume93
Issue number1-3
DOIs
StatePublished - Jul 1 2007

Keywords

  • Cholinesterase Inhibitors
  • Pharmacological Augmentation
  • Schizophrenia

Fingerprint Dive into the research topics of 'Double-blind donepezil-placebo crossover augmentation study of atypical antipsychotics in chronic, stable schizophrenia: A pilot study'. Together they form a unique fingerprint.

Cite this